Together we will beat cancer

Donate

ASCO 2021 news: follow-up treatments pave the way

One of the biggest meetings of the world’s cancer specialists took place this weekend. Here’s a flavour of the some of the top research presented.

Read More

ASCO 2019 news: targeted treatment takeover, drugging the ‘undruggable’, obesity and blood tests

The 2019 ASCO conference news highlights: a year of progress with targeted drugs trialled in prostate, pancreatic, breast and lung cancers.

Read More

Clearing up chemo options for frail and elderly patients with advanced oesophageal and stomach cancers

Older patients with advanced oesophageal and stomach cancers might benefit from low dose treatment, according to our unpublished clinical trial results.

Read More

ASCO 2018 news: ‘blood tests’, breast cancer chemo, kinder treatments and immunotherapy

The top stories from the 2018 ASCO annual meeting: overexcited coverage of cancer blood tests and how a gene test can tailor breast cancer treatment.

Read More

ASCO 2017: 4 ways treatment could change following world’s largest cancer conference

Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.

Read More

News digest – Improving prostate cancer survival, a life-extending app, yoga and… a tribute to Professor Patrick Johnston.

Improving prostate cancer survival, a life-extending app, yoga and our tribute to the remarkable Professor Patrick Johnston. Here’s our weekly news report.

Read More

‘Once in a career feeling’ as trial shows offering prostate cancer drug earlier improves survival

We take a look at results from the STAMPEDE clinical trial, which is researching how to improve treatment for men with prostate cancer.

Read More

ASCO 2016: will fine-tuning treatments require redefined tumours?

From immunotherapy to targeted cancer treatment, here’s our round up of the big news from the annual ASCO conference.

Read More

ASCO 2015 round-up: immunotherapy continues to come of age

We take a look back at the excitement from – and add a few important caveats to – the research from this year’s big US cancer conference.

Read More